Abstract: Disclosed is a system and method for identifying various combinations of parcels of land with sufficient transmission, resources, market demand, and available land to build a wind farm or solar farm. Different criteria associated with each parcel of land include land characteristics including size, ownership, tree coverage, elevations, terrain, buildable land, transmission characteristics including substation hardware costs, network upgrades, general tie-in costs, market characteristics including historical locational marginal pricing (LMPs), and resource characteristics including net capacity factor (NCF) of wind or solar. In one example, the present invention identifies clusters of land parcels that minimize the number of land owners, maximize buildable land, minimize transmission cost, maximize NCF, and maximize nodal LMPs.

Abstract: A method including the step of administering 2-hydroxypropyl-?-cyclodextrin (HP?CD) for use in the treatment of breast cancer. Particularly, this invention relates to HP?CD for use in the treatment of triple negative breast cancer, wherein the HP?CD is for administration to a patient in need thereof. The invention extends to methods of preparing a pharmaceutical composition comprising HP?CD, and further extends to a method of treating breast cancer, typically triple negative breast cancer, by administration of the composition to a patient in need thereof.

Abstract: In one embodiment, the invention provides methods of treatment which use therapeutically effective amounts of Cholesteryl Ester Transfer Protein (CETP) inhibitors to treat a variety of cancers. In certain embodiments, the inhibitor is a CETP-inhibiting small molecule, CETP-inhibiting antisense oligonucleotide, CETP-inhibiting siRNA or a CETP-inhibiting antibody. Related pharmaceutical compositions, kits, diagnostics and screens are also provided.

Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.

Abstract: In one embodiment, the invention provides methods of treatment which use therapeutically effective amounts of Cholesteryl Ester Transfer Protein (CETP) inhibitors to treat a variety of cancers. In certain embodiments, the inhibitor is a CETP-inhibiting small molecule, CETP-inhibiting antisense oligonucleotide, CETP-inhibiting siRNA or a CETP-inhibiting antibody. Related pharmaceutical compositions, kits, diagnostics and screens are also provided.

Abstract: Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.

Abstract: Controlling a software process by causing the execution of a first software process on a computer, where the first software process is configured to exclusively access a resource on the computer, causing the execution of a second software process on the computer when the first software process has exclusive access to the resource, where the second software process is configured to perform a first predefined action that is independent of the second software process accessing the resource, attempt to access the resource, and perform a second predefined action that is dependent on the second software process accessing resource, and causing the first software process to terminate its exclusive access to the resource, thereby causing the second software process to access the resource and perform the second predefined action.

Abstract: In one aspect, a method for detaching adherent cells can include adding a cell lifting solution to the media including a sample of adherent cells and incubating the sample of adherent cells with the cell lifting solution. No scraping or pipetting is needed to facilitate cell detachment. The method do not require inactivation of cell lifting solution and no washing of detaching cells is required to remove cell lifting solution. Detached cells can be stained with dye in the presence of cell lifting solution and are further analyzed using flow cytometer. The method has been tested using 6 different cell lines, 4 different assays, two different plate formats (96 and 384 well plates) and two different flow cytometry instruments. The method is simple to perform, less time consuming, with no cell loss and makes high throughput flow cytometry on adherent cells a reality.

Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.

Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.

Abstract: Controlling a software process by causing the execution of a first software process on a computer, where the first software process is configured to exclusively access a resource on the computer, causing the execution of a second software process on the computer when the first software process has exclusive access to the resource, where the second software process is configured to perform a first predefined action that is independent of the second software process accessing the resource, attempt to access the resource, and perform a second predefined action that is dependent on the second software process accessing resource, and causing the first software process to terminate its exclusive access to the resource, thereby causing the second software process to access the resource and perform the second predefined action.

Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.